Boehringer Ingelheim has a total of 593 patents globally, out of which 275 have been granted. Of these 593 patents, more than 23% patents are active. United States of America is where Boehringer Ingelheim has filed the maximum number of patents, followed by Europe and Canada. Parallelly, USA seems to be the main focused R&D center and Germany is the origin country of Boehringer Ingelheim.
Boehringer Ingelheim was founded in 1885 by Albert Boehringer. Boehringer Ingelheim operates as a pharmaceutical company. The Company researches, develops, and manufactures pharmaceutical products, as well as offers prescription medicines and consumer health care products for human and animal health. Boehringer Ingelheim serves clients worldwide.
Read about some of the most popular patents of Boehringer Ingelheim which have been covered by us in this article and also you can find Boehringer Ingelheim patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Boehringer Ingelheim patent portfolio.
How many patents does the Founder and CEO of Boehringer Ingelheim have?
The Founder Albert Boehringer have 0 patents and the CEO Jean-Michel Boers have 0 patents.
How many patents does Boehringer Ingelheim have?
Boehringer Ingelheim has a total of 593 patents globally. These patents belong to 136 unique patent families. Out of 593 patents, 140 patents are active.
How Many Patents did Boehringer Ingelheim File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Boehringer Ingelheim Applications Filed | Boehringer Ingelheim Patents Granted |
| 2011 | 5 | 20 |
| 2012 | 12 | 29 |
| 2013 | 5 | 23 |
| 2014 | 1 | 7 |
| 2015 | – | 8 |
| 2016 | 1 | 5 |
| 2017 | 3 | 5 |
| 2018 | 1 | 4 |
| 2019 | 3 | 2 |
| 2020 | 15 | – |
| 2021 | 8 | 1 |
Which Boehringer Ingelheim Drug Patents are Expiring in the Next 10 Years?
The patent no. US10406172B2 which is expiring in Jun, 2030, describes managing type 2 diabetes involves using an SGLT2 inhibitor, a DPPIV inhibitor, and another antidiabetic agent to prevent, slow, delay, or treat metabolic disorders in patients.
Given below is the list of few drugs patented by Boehringer Ingelheim accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Trijardy Xr | US10406172B2 | Pharmaceutical composition… | Jun, 2030 |
| Jentadueto | US10022379B2 | DPP-IV inhibitor combined with a… | Apr, 2029 |
| Tradjenta | US10034877B2 | Treatment for diabetes in patients… | Aug, 2029 |
| Glyxambi | US11033552B2 | DPP IV inhibitor formulations | May, 2027 |
| Jentadueto Xr | US8883805B2 | Process for the preparation of… | May, 2026 |
Interested in knowing about Boehringer Ingelheim Drug Patents Expiring in the next 10 years?
How many Boehringer Ingelheim patents are Alive/Dead?
Worldwide Patents
How Many Patents did Boehringer Ingelheim File in Different Countries?
Countries in which Boehringer Ingelheim Filed Patents
| Country | Patents |
| United States Of America | 43 |
| Europe | 42 |
| Canada | 26 |
| China | 25 |
| Australia | 24 |
| Hong Kong (S.A.R.) | 20 |
| Korea (South) | 20 |
| India | 19 |
| Japan | 18 |
| Spain | 18 |
| Germany | 18 |
| Austria | 16 |
| Portugal | 15 |
| Ukraine | 15 |
| Brazil | 15 |
| Mexico | 15 |
| Russia | 13 |
| Denmark | 13 |
| Argentina | 12 |
| Chile | 12 |
| Philippines | 12 |
| Indonesia | 11 |
| Israel | 10 |
| Poland | 10 |
| New Zealand | 10 |
| South Africa | 10 |
| Viet Nam | 9 |
| Taiwan | 8 |
| Singapore | 8 |
| Peru | 7 |
| Cyprus | 7 |
| Malaysia | 7 |
| Slovenia | 6 |
| United Kingdom | 6 |
| Ecuador | 4 |
| Uruguay | 3 |
| Norway | 3 |
| Morocco | 2 |
| Turkey | 2 |
| Tunisia | 2 |
| Serbia | 2 |
| Colombia | 2 |
| Croatia | 2 |
| Hungary | 2 |
| Finland | 1 |
| Guatemala | 1 |
| Luxembourg | 1 |
| Dominican Republic | 1 |
| Costa Rica | 1 |
| Lithuania | 1 |
| Africa | 1 |
| Honduras | 1 |
| Albania | 1 |
| Montenegro | 1 |
| Panama | 1 |
Where are Research Centers of Boehringer Ingelheim Patents Located?
10 Best Boehringer Ingelheim Patents
US6391314B1 is the most popular patent in the Boehringer Ingelheim portfolio. It has received 335 citations so far from companies like Zoetis Services Llc, Sbc Virbac Limited and Quantum Genetics Ireland Limited.
Below is the list of 10 most cited patents of Boehringer Ingelheim:
| Publication Number | Citation Count |
| US6391314B1 | 335 |
| US6368601B1 | 203 |
| WO2004096777A1 | 132 |
| US6660272B2 | 127 |
| US7122192B2 | 93 |
| US7192594B2 | 88 |
| US7144698B2 | 85 |
| US7211379B2 | 82 |
| US6776965B2 | 78 |
| WO2004084898A1 | 70 |
What Percentage of Boehringer Ingelheim US Patent Applications were Granted?
Boehringer Ingelheim (Excluding its subsidiaries) has filed 738 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 439 have been granted leading to a grant rate of 65.5%.
Below are the key stats of Boehringer Ingelheim patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Boehringer Ingelheim?
| Law Firm | Total Applications | Success Rate |
| C O Vp Ip Legal | 633 | 65.53% |
| Robert P Raymond | 11 | 90.91% |
| Dernier Ip Law Llc | 10 | 100.00% |
| Potomac Law Group Pllc | 7 | 60.00% |
| Wolf Greenfield & Sacks Pc | 6 | 100.00% |
| C O Ah Patent Department | 5 | 60.00% |
| Additon Pendleton & Witherspoon Pa | 4 | 0.00% |
| Sterne Kessler Goldstein & Fox Pllc | 4 | 50.00% |
| Alston & Bird Llp | 3 | 33.33% |
| Boehringer Ingelheim Animal Health Usa Inc | 3 | 0% |
EXCLUSIVE INSIGHTS COMING SOON!